Welcome to our dedicated page for Puretech Health news (Ticker: PRTC), a resource for investors and traders seeking the latest updates and insights on Puretech Health stock.
PureTech Health plc (PRTC) generates a steady flow of news as a hub-and-spoke biotherapeutics company advancing multiple clinical-stage programs through its own R&D engine and its Founded Entities. Company announcements frequently highlight clinical data, regulatory interactions, portfolio updates, and strategic developments tied to its capital-efficient model.
Recent news releases describe PureTech’s work in idiopathic pulmonary fibrosis via deupirfenidone (LYT-100), which is being advanced toward Phase 3 development by its Founded Entity Celea Therapeutics. Updates have included Phase 2b ELEVATE IPF trial results, open-label extension data, and sub-analyses in older patient populations, as well as regulatory meetings and planning for a pivotal Phase 3 trial. These stories provide insight into how PureTech and Celea are positioning deupirfenidone as a potential new standard of care in fibrotic lung disease.
News items also cover hematologic oncology through Gallop Oncology, another PureTech Founded Entity. Gallop has reported initial topline results from a Phase 1b trial of LYT-200 in relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndrome, including safety findings, response rates, and plans for a potentially registrational Phase 2 trial. Additional releases describe ongoing data presentations at major scientific meetings and continued maturation of survival data.
Beyond respiratory and oncology programs, PureTech’s news feed features updates from Seaport Therapeutics, such as the dosing of the first participant in a Phase 1 study of GlyphAgo (SPT-320) for generalized anxiety disorder, as well as corporate developments like leadership changes, half-year financial reports, and conference presentations including appearances at the J.P. Morgan Healthcare Conference. Investors and followers of PRTC can use this news page to track clinical milestones, strategic shifts, and the evolution of PureTech’s portfolio across its hub-and-spoke structure.
PureTech Health plc announces its plans to release the annual report and financial results on April 28, 2023, at 2:00 AM EDT. This report will encompass financial data for the year ending December 31, 2022, along with the cash balance for Q1 2023. A presentation and conference call to discuss the results will occur at 9:00 AM EDT on the same day, with a webcast available on the company's website. Additionally, PureTech is set to provide updates on its Wholly Owned Pipeline and Founded Entities, including its commitment to environmental, social, and governance (ESG) practices. The company, known for its innovative biotherapeutics, has developed a pipeline comprising 26 candidates, with notable FDA-clear therapies like Plenity® and EndeavorRx®.
Royalty Pharma has acquired an interest in PureTech’s royalty from Karuna Therapeutics for its therapy, KarXT, valued at up to $500 million. This includes $100 million upfront and potentially $400 million based on milestones. PureTech maintains its 3.1% equity stake in Karuna and will receive milestone payments and a share of sublicense revenues. The acquisition offers non-dilutive funding for PureTech’s pipeline, which includes five clinical-stage candidates expected by year-end.
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) has announced that its President, Bharatt Chowrira, and Chief Innovation Officer, Eric Elenko, will present at the Barclays Global Healthcare Conference on March 14 at 4:05 PM EDT. A webcast of the event will be available on the company's investor relations website. PureTech is focused on advancing innovative biotherapeutics aimed at altering treatment paradigms for serious diseases. The company boasts a diverse pipeline of 26 therapeutics, including FDA-cleared and European-authorized products. Stakeholders are encouraged to view the full press release for more details.
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) announced that its Founded Entity, Sonde Health, in collaboration with Massachusetts General Hospital (MGH), will lead a pilot study to use vocal biomarkers for the remote monitoring of mild cognitive impairment in individuals aged 55 and above. The project, funded by a $1.7 million grant from the Massachusetts Artificial Intelligence and Technology Center for Connected Care, will enroll 50 participants. It aims to assess the feasibility of using voice recordings to longitudinally track cognitive health at home, addressing the growing demand for in-home care solutions among older adults.
PureTech Health (Nasdaq: PRTC, LSE: PRTC) announces the advancement of LYT-300, an oral allopregnanolone candidate, for treating anxiety disorders and postpartum depression (PPD). A Phase 2a placebo-controlled trial for social anxiety in healthy volunteers will begin in H1 2023, with results expected by year-end. Additionally, an open-label Phase 2a trial for PPD in women is set for H2 2023. Previous Phase 1 results indicated that LYT-300 achieved therapeutic blood levels of allopregnanolone and was well tolerated. This neurosteroid is currently available only as a 60-hour intravenous infusion.
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) announced participation in the SVB Securities Global Biopharma Conference on February 15 at 10:40 am EST. CEO Daphne Zohar and Chief Innovation Officer Eric Elenko will host a fireside chat, which will be accessible via webcast at investors.puretechhealth.com. The company focuses on developing innovative treatments through a pipeline of 26 therapeutics, including FDA-cleared Plenity and EndeavorRx. PureTech aims to transform the treatment of serious diseases, aligning research with clinical insights.
Vedanta Biosciences, a clinical-stage biopharmaceutical company, announced participation in key investor conferences this January. The William Blair Biotech Private Company Conference will be held on January 30, 2023, featuring a virtual fireside chat at 2:00 PM ET. Subsequently, the SVB Securities Global Biopharma Conference will take place from January 31 to February 2, 2023, offering virtual 1x1 meetings. Vedanta Biosciences focuses on developing oral therapies using defined bacterial consortia to treat conditions like C. difficile infection and inflammatory bowel diseases. The company, founded by PureTech Health, holds 60+ patents and emphasizes microbiome research.
PureTech Health has announced positive topline results from its Phase 1 trial of LYT-300, an oral allopregnanolone therapy aimed at treating neurological conditions. The study demonstrated that LYT-300 achieved therapeutic blood levels of allopregnanolone and engaged GABAA receptors effectively. The therapy was well-tolerated with no severe adverse effects reported. The company plans to present additional trial data in a scientific forum and initiate a Phase 1b/2a trial in the first half of 2023, continuing its focus on innovative biotherapeutics.
PureTech Health will present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023, at 2:15 p.m. PST / 5:15 p.m. EST. The presentation will be led by Daphne Zohar, the Founder and CEO of the company. Interested parties can access the webcast at investors.puretechhealth.com. PureTech is a clinical-stage biotherapeutics company focused on advancing treatments for serious diseases. Their pipeline includes 28 therapeutics, including Plenity® and EndeavorRx®, which have received FDA clearance.
PureTech Health plc announced data highlighting LYT-200, a monoclonal antibody targeting galectin-9, as a promising treatment for leukemia. The data, presented at the American Society of Hematology Annual Meeting, suggest significant anti-tumor activity across various leukemia types. A clinical trial evaluating LYT-200 in acute myeloid leukemia (AML) has begun, with results expected in 2023. The company’s ongoing Phase 1 trial has shown safety in escalating doses and effective anti-cancer activity, indicating a potential new therapeutic avenue for patients with poor survival rates.